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crisis of chronic myeloid leukemiaDear Editor
We report the clinical findings of a study on a 29-year-old
woman diagnosed with chronic myeloid leukemia (CML)
blast crisis with an initial presentation of cardiac tampo-
nade. She first visited our hospital because of dyspnea
experienced for 1 month. Other associated symptoms were
abdominal fullness and bilateral lower leg pitting edema.
She denied having any underlying disease. At the time of
admission, her blood pressure was 82/50 mmHg and pulse
rate was 120/min, with a marked paradoxical pulse. Initial
laboratory findings revealed a white blood cell count of
614  103/mL, hemoglobin level of 4.6 g/dL, and platelet
counts of 198,000/mL. The differential blood count showed
45% blasts, 10% promyelocytes, 4% myelocytes, 1% baso-
phils, and 1% eosinophils, with normocytic normochromic
erythrocytes (Figure 1B). Renal and liver functions were
normal. An abdominal computed tomography scan revealed
massive splenomegaly (Figure 1A), and bone marrow ex-
amination revealed hypercellularity, with a myeloid/
erythroid ratio of 13:1 and 65% blasts. Moreover, the Phil-
adelphia chromosome was observed in all analyzed meta-
phases, and polymerase chain reaction revealed a bcr-abl
rearrangement on P210 (b3a2). Flow cytometry revealed
96% CD33, 93% CD13, and an aberrant expression of CD7
and CD15. The diagnosis was Philadelphia-positive CML in
blast crisis and a change in acute myeloid leukemia.
Echocardiography showed a massive pericardial effusion
with cardiac tamponade (Figure 1C). Furthermore, peri-
cardial fluid cytology revealed leukemic cell infiltration
(Figure 1D). No bacteria, fungi, or acid-fast bacilli were
observed on repeated examinations. The patient was
administered hydroxyurea, normal saline hydration
(2500 mL/d), low-dose cytarabine (20 mg/m2/d) for 5 days,
and dasatinib (100 mg/d). Pericardiocentesis drainage was
also performed, and initially 1200 mL of yellowishConflicts of interest: All authors declare no conflicts of interest.
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tient’s symptoms improved considerably, and she was
discharged.
Fifty percent of patients with CML are asymptomatic at
initial presentation, and CML is often diagnosed during a
routine general health blood test or an abnormal hemo-
gram. The most common symptoms of CML are fatigue,
abdominal fullness, and left upper quadrant fullness.
Pericardial effusion is a rare complication of CML and
typically occurs in the chronic phase of CML [1]. Cardiac
tamponade as the initial presentation in CML blast crisis is
extremely rare; to date, only four cases have been reported
[2e5], which occurred before the year 2000.
In a patient with acute leukemia harboring Philadelphia/
BCR-ABL, the bcr-abl rearrangement often revealed P190,
and a hemogram usually revealed thrombocytopenia. In our
case, the bcr-abl rearrangement revealed P210 (b3a2), the
most common rearrangement area of CML. The hemogram
revealed normal platelet counts with eosinophilia and
basophilia, and physical examination revealed splenomeg-
aly. The final diagnosis was blast crisis of CML.
The causes of pericardial effusion may be associated
with leukemic cell infiltration, extramedullary hematopoi-
esis, infection, and bleeding in patients with CML. In our
case, the mechanism of cardiac tamponade was leukemic
cell infiltration (Figure 1D). The National Comprehensive
Cancer Network guideline for treatment with CML blast
crisis includes induction chemotherapy with a tyrosine ki-
nase inhibitor (TKI) followed by hematopoietic cell trans-
plantation (HCT) or TKI followed by HCT. In our article, the
treatment was hydroxyurea, normal saline hydration
(2500 mL/d), low-dose cytarabine (20 mg/m2/d) for 5 days,
and TKI (dasatinib; 100 mg/d). Two years later, we checked
the molecular response of BCR-ABL which revealed 3.2 log
reduction (a major molecular response). We will arrange
hematopoietic cell transplantation in the future. The
outcome of cardiac tamponade as the initial presentation in
CML blast crisis cited in the literature [2e5] was invariably
fatal. Because in previous cases treatment was just withy Elsevier Taiwan LLC. This is an open access article under the CC
).
Figure 1. (A) An abdominal computed tomography scan revealed massive splenomegaly (arrow). (B) Initial laboratory findings
revealed a white blood cell count of 614 103/mL with 45% blasts (arrow; original magnification, 1000). (C) Echocardiography
showed a massive pericardial effusion with cardiac tamponade (arrow). (D) Pericardial fluid cytology revealed leukemic cell
infiltration (arrow; original magnification, 400).
Letter to the Editor 161hydroxyurea and pericardiocentesis, there was no treat-
ment with TKI or HCT.
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